Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TEGRETOL | Novartis | N-016608 RX | 1982-01-01 | 1 products, RLD, RS |
TEGRETOL | Novartis | N-018927 RX | 1987-12-18 | 1 products, RLD, RS |
TEGRETOL-XR | Novartis | N-020234 RX | 1996-03-25 | 3 products, RLD, RS |
CARBATROL | Takeda | N-020712 RX | 1997-09-30 | 3 products, RLD |
EQUETRO | Validus Pharmaceuticals | N-021710 RX | 2004-12-10 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
carbamazepin carbamazepine | ANDA | 2023-10-19 |
carbamazepine | ANDA | 2024-02-02 |
carbamazepine er | ANDA | 2024-01-03 |
carbatrol | New Drug Application | 2023-04-17 |
carbatrol extended-release | 2007-03-30 | |
carnexiv | New Drug Application | 2024-01-09 |
epitol | ANDA | 2022-03-22 |
equetro | New Drug Application | 2022-10-13 |
hand sanitizer | OTC monograph not final | 2021-11-30 |
tegretol | New Drug Application | 2023-09-13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Epilepsy | D004827 | EFO_0000474 | G40.9 | 4 | 2 | 9 | 8 | 11 | 33 |
Healthy volunteers/patients | — | — | — | 15 | — | — | 1 | 1 | 17 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 1 | 3 | 10 | 2 | 16 |
Seizures | D012640 | HP_0002069 | G40.4 | — | — | 4 | 1 | 4 | 9 |
Partial epilepsies | D004828 | EFO_0004263 | — | — | — | 1 | 3 | — | 4 |
Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | — | 1 | 1 | 1 | 2 | 4 |
Cocaine-related disorders | D019970 | — | F14 | — | 3 | — | 1 | — | 4 |
Rolandic epilepsy | D019305 | — | — | — | — | — | 3 | — | 3 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | 1 | — | 3 |
Neuralgia | D009437 | EFO_0009430 | — | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | — | 1 | — | — | 2 |
Tuberous sclerosis | D014402 | HP_0009720 | Q85.1 | — | — | 1 | — | — | 1 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | — | 1 |
Tonic-clonic epilepsy | D004830 | EFO_0007262 | — | — | — | 1 | — | — | 1 |
Generalized epilepsy | D004829 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | — | 1 |
Alpha 1-antitrypsin deficiency | D019896 | — | E88.01 | — | 1 | — | — | — | 1 |
Reflex epilepsy | D020195 | EFO_1001146 | — | — | 1 | — | — | — | 1 |
Infantile spasms | D013036 | HP_0011097 | G40.82 | — | 1 | — | — | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Vomiting | D014839 | HP_0002013 | R11.1 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioblastoma | D005909 | EFO_0000515 | — | 4 | — | — | — | — | 4 |
Gliosarcoma | D018316 | — | — | 4 | — | — | — | — | 4 |
Astrocytoma | D001254 | EFO_0000271 | — | 3 | — | — | — | — | 3 |
Covid-19 | D000086382 | — | U07.1 | 2 | — | — | — | — | 2 |
Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | — | — | — | — | 1 |
Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
Hot flashes | D019584 | — | — | 1 | — | — | — | — | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | — | 1 | 1 |
Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | — | 1 | 1 |
Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | — | — | 1 | 1 |
Drug hypersensitivity syndrome | D063926 | EFO_1002004 | D72.12 | — | — | — | — | 1 | 1 |
Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 1 | 1 |
Autistic disorder | D001321 | HP_0000717 | F84.0 | — | — | — | — | 1 | 1 |
Cognition disorders | D003072 | — | — | — | — | — | — | 1 | 1 |
Postherpetic neuralgia | D051474 | — | — | — | — | — | — | 1 | 1 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 1 | 1 |
Drug common name | Carbamazepine |
INN | carbamazepine |
Description | Carbamazepine is a dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. It has a role as an anticonvulsant, an EC 3.5.1.98 (histone deacetylase) inhibitor, a mitogen, a glutamate transporter activator, an antimanic drug, an analgesic, a non-narcotic analgesic, an environmental contaminant, a xenobiotic, a drug allergen and a sodium channel blocker. It is a dibenzoazepine and a member of ureas. |
Classification | Small molecule |
Drug class | tricyclic compounds |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)N1c2ccccc2C=Cc2ccccc21 |
PDB | — |
CAS-ID | 298-46-4 |
RxCUI | — |
ChEMBL ID | CHEMBL108 |
ChEBI ID | 3387 |
PubChem CID | 2554 |
DrugBank | DB00564 |
UNII ID | 33CM23913M (ChemIDplus, GSRS) |